<p>根据 MarketBeat.com 报道，覆盖 Biodesix, Inc.（NASDAQ:BDSX - 获取免费报告）的六家研究公司对其股票给予了 “适度买入” 的平均评级。一位研究分析师给予该股票卖出建议，一位给予持有建议，四位给予买入建议。在过去一年中，覆盖该股票的分析师的平均一年目标价为 32.50 美元。</p>
<p>几家券商最近对 BDSX 发布了报告。Weiss Ratings 在 12 月 22 日的研究报告中重新发布了对 Biodesix 股票的 “卖出（e+）” 评级。华尔街 Zen 在 11 月 8 日的报告中将 Biodesix 的评级从 “卖出” 上调至 “持有”。</p>
<p><strong>查看我们关于 Biodesix 的最新报告</strong></p>
<h2>Biodesix 价格表现</h2>
<p>Biodesix 股票在周二开盘价为 9.93 美元。Biodesix 的一年低点为 3.44 美元，一年高点为 20.40 美元。该公司的债务与股本比率为 41.11，速动比率为 1.84，流动比率为 1.84。该公司的 50 日移动平均价格为 8.25 美元，200 日移动平均价格为 7.94 美元。公司的市值为 7904 万美元，市盈率为 -1.79，贝塔值为 0.66。</p>
<h2>Biodesix 的内部买卖</h2>
<p>在其他新闻中，董事 Jack W. Schuler 于 1 月 22 日以每股平均 10.96 美元的价格收购了 82,465 股 Biodesix 股票，总价值为 903,816.40 美元。购买后，该董事直接持有公司股票 1,463,210 股，价值约为 16,036,781.60 美元。这笔交易代表其持股比例增加了 5.97%。该收购在向证券交易委员会的备案中披露，相关文件可在此链接查看。在过去一个季度，内部人士购买了价值 2,084,616 美元的 182,465 股公司股票，并出售了价值 15,868 美元的 1,947 股。30.10% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>对该公司的对冲基金最近进行了买卖。阿伯丁集团（Aberdeen Group plc）在第四季度购买了 Biodesix 的新股份，价值约为 1,784,000 美元。XTX Topco Ltd 在第二季度将其在 Biodesix 的持股增加了 99.4%。XTX Topco Ltd 现在拥有 205,647 股公司股票，价值 58,000 美元，此前在上个季度又收购了 102,494 股。Geode Capital Management LLC 在第四季度将其在 Biodesix 的持股增加了 5.6%。Geode Capital Management LLC 现在拥有 42,453 股公司股票，价值 289,000 美元，此前在此期间又购买了 2,235 股。Oracle Investment Management Inc. 在第三季度购买了 Biodesix 的新股份，价值 113,000 美元。最后，千禧管理公司（Millennium Management LLC）在第三季度收购了 Biodesix 的新股份，价值 113,000 美元。对冲基金和其他机构投资者持有公司 20.96% 的股票。</p>
<h2>Biodesix 公司简介</h2>
<p>（获取免费报告）</p>
<p>Biodesix, Inc 是一家总部位于科罗拉多州博尔德的商业阶段分子诊断公司，开发和提供基于血液的测试，以改善肺部疾病（包括肺癌）的诊断和管理。该公司整合了先进的蛋白质组学和最近的基因组技术，提供旨在指导临床决策的非侵入性测试解决方案。Biodesix 运营着一家 CLIA 认证和 CAP 认可的实验室，能够大规模处理患者样本并保持严格的质量标准。</p>
<p>该公司的旗舰产品 VeriStrat® 是一种蛋白质组学测试，将非小细胞肺癌患者分层为更可能从特定疗法中受益的组别。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Biodesix 更好</li>
<li>没有人谈论的买入狂潮</li>
<li>如何每周收集 500-800 美元（黑石的系统）</li>
<li>特朗普的 AI 秘密：比英伟达快 100 倍</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>他们刚刚试图扼杀黄金</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Biodesix 吗？</h2>
<p>在考虑 Biodesix 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Biodesix 并不在名单上。</p>
<p>虽然 Biodesix 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>在这里查看这五只股票</p>

动态生物技术与基因组 ETF - Invesco

基因免疫&健康关怀 ETF - iShares

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

BDSX

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

医药突破 ETF - ALPS

纽交所高增长板生物技术指数 ETF - First Trust

<p>Biodesix, Inc.（纳斯达克代码：BDSX）获得了六家研究公司的 “适度买入” 平均评级。一位分析师将其评级为卖出，一位为持有，四位为买入。平均一年目标价为 32.50 美元。该股票开盘价为 9.93 美元，1 年最低价为 3.44 美元，最高价为 20.40 美元。内部人士 Jack W. Schuler 以每股 10.96 美元的价格购买了 82,465 股。对冲基金持有该股票的 20.96%。Biodesix 专注于肺部疾病的血液检测，并运营一家 CLIA 认证的实验室</p>

<p>Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have been given an average rating of &#34;Moderate Buy&#34; by the six research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $32.50.</p>
<div class="lb-trans"><p>根据 MarketBeat.com 报道，覆盖 Biodesix, Inc.（NASDAQ:BDSX - 获取免费报告）的六家研究公司对其股票给予了 “适度买入” 的平均评级。一位研究分析师给予该股票卖出建议，一位给予持有建议，四位给予买入建议。在过去一年中，覆盖该股票的分析师的平均一年目标价为 32.50 美元。</p>
</div><p>Several brokerages have recently issued reports on BDSX. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Biodesix in a research note on Monday, December 22nd. Wall Street Zen upgraded Biodesix from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 8th.</p>
<div class="lb-trans"><p>几家券商最近对 BDSX 发布了报告。Weiss Ratings 在 12 月 22 日的研究报告中重新发布了对 Biodesix 股票的 “卖出（e+）” 评级。华尔街 Zen 在 11 月 8 日的报告中将 Biodesix 的评级从 “卖出” 上调至 “持有”。</p>
</div><p><strong>View Our Latest Report on Biodesix</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Biodesix 的最新报告</strong></p>
</div><h2>Biodesix Price Performance</h2>
<div class="lb-trans"><h2>Biodesix 价格表现</h2>
</div><p>Biodesix stock opened at $9.93 on Tuesday. Biodesix has a 1 year low of $3.44 and a 1 year high of $20.40. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84. The firm has a 50 day moving average price of $8.25 and a 200 day moving average price of $7.94. The company has a market cap of $79.04 million, a price-to-earnings ratio of -1.79 and a beta of 0.66.</p>
<div class="lb-trans"><p>Biodesix 股票在周二开盘价为 9.93 美元。Biodesix 的一年低点为 3.44 美元，一年高点为 20.40 美元。该公司的债务与股本比率为 41.11，速动比率为 1.84，流动比率为 1.84。该公司的 50 日移动平均价格为 8.25 美元，200 日移动平均价格为 7.94 美元。公司的市值为 7904 万美元，市盈率为 -1.79，贝塔值为 0.66。</p>
</div><h2>Insider Buying and Selling at Biodesix</h2>
<div class="lb-trans"><h2>Biodesix 的内部买卖</h2>
</div><p>In other news, Director Jack W. Schuler acquired 82,465 shares of Biodesix stock in a transaction dated Thursday, January 22nd. The shares were acquired at an average cost of $10.96 per share, with a total value of $903,816.40. Following the purchase, the director directly owned 1,463,210 shares of the company's stock, valued at approximately $16,036,781.60. This trade represents a 5.97% increase in their position. The acquisition was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this link. Over the last quarter, insiders bought 182,465 shares of company stock valued at $2,084,616 and sold 1,947 shares valued at $15,868. 30.10% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Jack W. Schuler 于 1 月 22 日以每股平均 10.96 美元的价格收购了 82,465 股 Biodesix 股票，总价值为 903,816.40 美元。购买后，该董事直接持有公司股票 1,463,210 股，价值约为 16,036,781.60 美元。这笔交易代表其持股比例增加了 5.97%。该收购在向证券交易委员会的备案中披露，相关文件可在此链接查看。在过去一个季度，内部人士购买了价值 2,084,616 美元的 182,465 股公司股票，并出售了价值 15,868 美元的 1,947 股。30.10% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Hedge funds have recently bought and sold shares of the business. Aberdeen Group plc purchased a new stake in Biodesix during the fourth quarter worth approximately $1,784,000. XTX Topco Ltd lifted its holdings in shares of Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock valued at $58,000 after acquiring an additional 102,494 shares in the last quarter. Geode Capital Management LLC boosted its position in Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company's stock worth $289,000 after purchasing an additional 2,235 shares during the period. Oracle Investment Management Inc. purchased a new stake in Biodesix during the 3rd quarter worth $113,000. Finally, Millennium Management LLC acquired a new stake in Biodesix in the 3rd quarter valued at $113,000. Hedge funds and other institutional investors own 20.96% of the company's stock.</p>
<div class="lb-trans"><p>对该公司的对冲基金最近进行了买卖。阿伯丁集团（Aberdeen Group plc）在第四季度购买了 Biodesix 的新股份，价值约为 1,784,000 美元。XTX Topco Ltd 在第二季度将其在 Biodesix 的持股增加了 99.4%。XTX Topco Ltd 现在拥有 205,647 股公司股票，价值 58,000 美元，此前在上个季度又收购了 102,494 股。Geode Capital Management LLC 在第四季度将其在 Biodesix 的持股增加了 5.6%。Geode Capital Management LLC 现在拥有 42,453 股公司股票，价值 289,000 美元，此前在此期间又购买了 2,235 股。Oracle Investment Management Inc. 在第三季度购买了 Biodesix 的新股份，价值 113,000 美元。最后，千禧管理公司（Millennium Management LLC）在第三季度收购了 Biodesix 的新股份，价值 113,000 美元。对冲基金和其他机构投资者持有公司 20.96% 的股票。</p>
</div><h2>Biodesix Company Profile</h2>
<div class="lb-trans"><h2>Biodesix 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.</p>
<div class="lb-trans"><p>Biodesix, Inc 是一家总部位于科罗拉多州博尔德的商业阶段分子诊断公司，开发和提供基于血液的测试，以改善肺部疾病（包括肺癌）的诊断和管理。该公司整合了先进的蛋白质组学和最近的基因组技术，提供旨在指导临床决策的非侵入性测试解决方案。Biodesix 运营着一家 CLIA 认证和 CAP 认可的实验室，能够大规模处理患者样本并保持严格的质量标准。</p>
</div><p>The company's flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.</p>
<div class="lb-trans"><p>该公司的旗舰产品 VeriStrat® 是一种蛋白质组学测试，将非小细胞肺癌患者分层为更可能从特定疗法中受益的组别。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Biodesix</li>
<li>The buying spree that no one is talking about</li>
<li>How to collect $500-$800 weekly (BlackRock's system)</li>
<li>Trump’s AI Secret: 100X Faster Than Nvidia</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>They just tried to kill gold</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Biodesix 更好</li>
<li>没有人谈论的买入狂潮</li>
<li>如何每周收集 500-800 美元（黑石的系统）</li>
<li>特朗普的 AI 秘密：比英伟达快 100 倍</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>他们刚刚试图扼杀黄金</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=BDSX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Biodesix Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Biodesix 吗？</h2>
</div><p>Before you consider Biodesix, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Biodesix 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodesix wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Biodesix 并不在名单上。</p>
</div><p>While Biodesix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Biodesix 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Biodesix, Inc. (NASDAQ:BDSX) Receives Average Rating of "Moderate Buy" from Brokerages

Market Beat

Biodesix

Biodesix, Inc. (NASDAQ:BDSX) 被券商给予 “适度买入” 的平均评级